FindTrial
Sign In

BG00002 (natalizumab)

DRUG5 trials

Sponsors

Biogen

Conditions

Multiple MyelomaMultiple SclerosisMultiple Sclerosis, Relapsing-RemittingRelapsing Remitting Multiple SclerosisRelapsing Remitting Multiple Sclerosis (RRMS)

Phase 1

Study of Natalizumab in Relapsed/Refractory Multiple Myeloma
TerminatedNCT00675428
BiogenMultiple Myeloma
Start: 2008-09-30End: 2009-12-31Updated: 2014-09-19

Phase 3

Natalizumab Re-Initiation of Dosing
CompletedNCT00306592
BiogenMultiple Sclerosis, Relapsing-Remitting
Start: 2006-03-31End: 2008-02-29Updated: 2017-03-21
Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis
TerminatedNCT01058005
BiogenRelapsing Remitting Multiple Sclerosis
Start: 2010-03-31End: 2012-04-30Updated: 2014-09-03

Phase 4

The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis
CompletedNCT00536120
BiogenMultiple Sclerosis
Start: 2008-01-31End: 2009-12-31Updated: 2017-02-15
A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients
CompletedNCT00871780
BiogenRelapsing Remitting Multiple Sclerosis (RRMS)
Start: 2009-08-31End: 2012-07-31Updated: 2017-03-21